RJT-101

camptothecin derivative

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

1.	Melanoma (Melanoma, Malignant) 01/01/2020 - "RJT-101 significantly inhibits the proliferation of melanoma cells, however has low cytotoxicity to non-malignant cells. " 01/01/2020 - "RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1." 01/01/2020 - "RJT-101 effectively inhibits melanoma cells (including vemurafenib-resistant melanoma cells) proliferation in vitro and in vivo through the induction of DNA damage and apoptosis by inhibiting of Top1, indicating RJT-101 warrants further clinical evaluation."
2.	Neoplasms (Cancer) 01/01/2020 - "RJT-101 induces apoptosis, DNA damage, and G2/M phase arrest, as a consequent, attenuates tumor growth, lung metastasis in vivo as well as prolongs survival of tumor bearing mice. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2020 - "RJT-101 induces apoptosis, DNA damage, and G2/M phase arrest, as a consequent, attenuates tumor growth, lung metastasis in vivo as well as prolongs survival of tumor bearing mice. "